Streetwise Reports' Article Archives — June 2018 back to current month (10)
An H.C. Wainwright & Co. report highlighted the advantages, status and potential of this lead asset.
A Maxim Group note discussed the latest clinical endeavor involving a three-pronged approach targeting glioblastoma.
This precision medicine company, focused on neurodegenerative diseases, has selected antibody candidates to advance into the final phase of discovery.
This medical device company enters a partnership to provide quality and regulatory services.
A B. Riley FBR report provided an overview of this life sciences firm.
A BTIG report reviewed the news announced by this supplier of blood grouping reagents and control products.
Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease.
An H.C. Wainwright & Co. report relayed the highlights of the new trial data from this Israel-based firm.
A technology company that develops mobile health and telemedicine platforms for community-based healthcare has raised money, made a deal that will accelerate the number of patients it adds every month, and is breaking through its hardware logjam.
A Canaccord Genuity analyst provided an update on this late-stage Canadian life sciences firm targeting metastatic breast cancer.
|"From a stock perspective, 2019 was a clear breakout year for DRRX."|